Payment overview · 2025
General Payments
$122.02
7 reported records · 6 companies
Healthcare provider profile · identity verified
Patrick W Tester, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LELAND, NC · NPI 1649263617
Verified facts
What the public records show
CMS Open Payments records show Patrick W Tester, MD received $122.02 in general payments during 2025 across 7 reported records.
Novo Nordisk Inc accounted for 32.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $39.44 | 32.3% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $18.74 | 15.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.38 | 14.2% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.58 | 13.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.94 | 13.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.94 | 11.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $122.02 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.59 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $18.74 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.38 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.38 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $16.58 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.94 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.94 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 83 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
83 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 991 | 259 |
| Amlodipine Besylate | Amlodipine Besylate | 517 | 142 |
| Losartan Potassium | Losartan Potassium | 361 | 106 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 353 | 99 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 317 | 91 |
| Omeprazole | Omeprazole | 284 | 79 |
| Lisinopril | Lisinopril | 256 | 69 |
| Levothyroxine Sodium | Levothyroxine Sodium | 248 | 67 |
| Metoprolol Succinate | Metoprolol Succinate | 196 | 55 |
| Zolpidem Tartrate | Zolpidem Tartrate | 191 | 37 |
| Simvastatin | Simvastatin | 190 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 179 | 47 |
| Metformin Hcl Er | Metformin Hcl | 152 | 43 |
| Fluticasone Propionate | Fluticasone Propionate | 149 | 60 |
| Pravastatin Sodium | Pravastatin Sodium | 139 | 37 |
| Meloxicam | Meloxicam | 135 | 42 |
| Gabapentin | Gabapentin | 122 | 45 |
| Glimepiride | Glimepiride | 119 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 119 | 44 |
| Metformin Hcl | Metformin Hcl | 116 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 115 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 111 | 33 |
| Pioglitazone Hcl | Pioglitazone Hcl | 105 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 104 | 28 |
| Fluoxetine Hcl | Fluoxetine Hcl | 91 | 27 |
| Famotidine | Famotidine | 90 | 26 |
| Allopurinol | Allopurinol | 88 | 24 |
| Synthroid | Levothyroxine Sodium | 86 | 18 |
| Furosemide | Furosemide | 83 | 28 |
| Ozempic | Semaglutide | 83 | 22 |
| Potassium Chloride | Potassium Chloride | 83 | 27 |
| Montelukast Sodium | Montelukast Sodium | 78 | 26 |
| Eliquis | Apixaban | 76 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 71 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 71 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 70 | 18 |
| Trazodone Hcl | Trazodone Hcl | 68 | 17 |
| Bupropion Xl | Bupropion Hcl | 67 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 66 | 16 |
| Alprazolam | Alprazolam | 60 | 24 |
| Sertraline Hcl | Sertraline Hcl | 59 | 19 |
| Xarelto | Rivaroxaban | 56 | 14 |
| Atenolol | Atenolol | 52 | 16 |
| Spironolactone | Spironolactone | 50 | 15 |
| Carvedilol | Carvedilol | 47 | 12 |
| Prednisone | Prednisone | 45 | 30 |
| Valsartan | Valsartan | 45 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 40 | 19 |
| Donepezil Hcl | Donepezil Hcl | 36 | 11 |
| Lovastatin | Lovastatin | 36 | 12 |
| Clonazepam | Clonazepam | 34 | suppressed |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Celecoxib | Celecoxib | 33 | suppressed |
| Chlorthalidone | Chlorthalidone | 33 | 11 |
| Finasteride | Finasteride | 33 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 33 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 31 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 30 | suppressed |
| Lorazepam | Lorazepam | 29 | suppressed |
| Glipizide | Glipizide | 28 | suppressed |
| Jardiance | Empagliflozin | 28 | suppressed |
| Pregabalin | Pregabalin | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 20 |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Levemir Flexpen | Insulin Detemir | 22 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 22 |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Jantoven | Warfarin Sodium | 18 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Azithromycin | Azithromycin | 14 | 13 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Acebutolol Hcl | Acebutolol Hcl | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 12 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $122.02 · 7 records | Novo Nordisk Inc | BREZTRI, GVOKE HYPOPEN, MOUNJARO, OTEZLA, Ozempic, REPATHA, Rybelsus, Veozah, Wegovy, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error